Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Cleveland Biolabs, Inc. (NQ: CBLI)
1.640 USD  UNCHANGED
Official Closing Price  /  Updated: 8:10 PM EDT, May 23, 2013  /  Add to My Watchlist      
View: Quote News Research
Press releases about Cleveland Biolabs, Inc.
 
< Previous 1 2 3 4 5 6 7 8 9 Next >
Cleveland BioLabs to Present at Second Annual Marcum LLP Microcap Conference
May 22, 2013
from PR Newswire
Cleveland BioLabs and Incuron Announce US and European Patent Allowances for Curaxins
May 14, 2013
from GlobeNewswire News Releases
CORRECTION -- Cleveland BioLabs Reports First Quarter 2013 Financial Results and Development Progress
May 09, 2013
from GlobeNewswire News Releases
Cleveland BioLabs Reports First Quarter 2013 Financial Results and Development Progress
May 09, 2013
from GlobeNewswire News Releases
Cleveland BioLabs Announces Appointment of Shareholder Representative to Board
May 08, 2013
2013 Annual Meeting of Stockholders June 14 Read More
from GlobeNewswire News Releases
Cleveland BioLabs, Roswell Park Announce Publication of Studies Defining Role of Liver in Activity of Entolimod (CBLB502)
May 01, 2013
from GlobeNewswire News Releases
Cleveland BioLabs to Report First Quarter 2013 Financial Results and Provide Operational Update on May 9
April 30, 2013
from GlobeNewswire News Releases
Cleveland BioLabs Announces Changes to Board of Directors
April 23, 2013
from GlobeNewswire News Releases
Cleveland BioLabs Strengthens Clinical Development Team
April 08, 2013
from GlobeNewswire News Releases
Cleveland BioLabs and Incuron Announce Notice of Allowance From FDA to Commence Clinical Testing With CBL0137
April 02, 2013
from GlobeNewswire News Releases
Free Research Reports on CBLI, DRYS, HALO and QCOR Issued by the Bedford Report
March 25, 2013
Note to Editors: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS CIRCUIT Read More
from Marketwired News Releases
Cleveland BioLabs Reports Fourth Quarter and Fiscal 2012 Financial Results and Development Progress
March 14, 2013
from GlobeNewswire News Releases
Cleveland BioLabs to Report Fiscal 2012 Financial Results and Provide Operational Update on March 14
March 08, 2013
from GlobeNewswire News Releases
Free Research Reports on CBLI, GALE, GLUU and SAN Issued by the Bedford Report
February 05, 2013
Note to Editors: The Following Is an Investment Opinion Being Issued by the Equity News Circuit Read More
from Marketwired News Releases
Number of FDA Drug Approvals Reach a 15-Year High in 2012
February 05, 2013
Research Driven Investing Provides Stocks Research on Cleveland BioLabs and Hyperion Therapeutics Read More
from Marketwired News Releases
Cleveland BioLabs to Present at 15th Annual BIO CEO and Investor Conference
February 05, 2013
from GlobeNewswire News Releases
Cleveland BioLabs to Present at BARDA and NIAID Sponsored Symposium on Development of Radiation Medical Countermeasures
January 24, 2013
from GlobeNewswire News Releases
Cleveland BioLabs to Present at Oppenheimer 23rd Annual Healthcare Conference
December 04, 2012
from GlobeNewswire News Releases
Panacela Labs, a Subsidiary of Cleveland BioLabs, Signs Contract for Approximately $4.6 Million With Russian Ministry of Industry and Trade for Development of Xenomycins
November 27, 2012
from GlobeNewswire News Releases
Cleveland BioLabs Reports Third Quarter 2012 Financial Results and Development Progress
November 08, 2012
from GlobeNewswire News Releases
Cleveland BioLabs Announces Publication of Studies on Effect of Entolimod(TM) (CBLB502) on Graft-Versus-Tumor Activity in Models of Allogeneic Bone Marrow Transplantation
November 06, 2012
from GlobeNewswire News Releases
Cleveland BioLabs to Report Third Quarter Financial Results and Provide Operational Update on November 8
October 30, 2012
from GlobeNewswire News Releases
Department of Defense Chemical Biological and Medical Systems Continues Funding Under Development Contract With Cleveland BioLabs for Entolimod(TM) (CBLB502)
October 25, 2012
from GlobeNewswire News Releases
Cleveland BioLabs Prices $15 Million Public Offering of Common Stock and Warrants
October 19, 2012
from GlobeNewswire News Releases
Cleveland BioLabs Announces Proposed Public Offering of Common Stock and Warrants
October 18, 2012
from GlobeNewswire News Releases
Cleveland BioLabs Submits Proposal to BARDA for Development Funding for Entolimod(TM) (CBLB502)
October 18, 2012
from GlobeNewswire News Releases
Cleveland BioLabs and Incuron Announce Start of Phase 1 Trial for CBL0137
October 10, 2012
from GlobeNewswire News Releases
Department of Defense Defense Threat Reduction Agency Increases Development Contract With Cleveland BioLabs for Entolimod(TM) (CBLB502)
October 04, 2012
from GlobeNewswire News Releases
Cleveland BioLabs and Incuron Announce CBL0102 Orphan Drug Status for Hepatocellular Carcinoma
October 02, 2012
from GlobeNewswire News Releases
Cleveland BioLabs Receives FDA Meeting Minutes and Advice Letter on Clinical Protocol for Development of Entolimod(TM) (CBLB502) as Radiation Countermeasure
October 01, 2012
from GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here